Articles

PP23 A simple frailty score to identify patients with malignant hemopathies who don’t benefit from standard dose chemotherapy

BJH - 2018, issue Abstract Book BHS, february 2018

S. Dubruille PhD, C. Kenis , Y. Libert PhD, M. Delforge MD, PhD, L. Dal Lago , M. Roos , C. Borghgraef , A. Salaroli MD, M. Maerevoet MD, D. Razavi MD, PhD, H. Wildiers , D. Bron MD, PhD

Read more

O.1 A new frailty scoring in ‘clinically fit’ older patients with malignant hemopathies admitted to receive chemotherapy

BJH - volume 8, issue Abstract Book BHS, february 2017

S. Dubruille PhD, C. Kenis , Y. Libert PhD, M. Delforge MD, PhD, J. Alexis Ruiz , M. Roos , A. Collard , N. Meuleman MD, PhD, M. Maerevoet MD, D. Razavi MD, PhD, H. Wildiers , D. Bron MD, PhD

Read more

Onco-haematology geriatry: impact of cognitive disorders

BJH - volume 7, issue 5, october 2016

S. Dubruille PhD, Y. Libert PhD, D. Razavi MD, PhD, D. Bron MD, PhD

Summary

A Comprehensive Geriatric Assessment is recommended to detect vulnerable cancer patients for whom chemotherapy may lead to severe impairment on functionality, quality of life, or survival. Although Comprehensive Geriatric Assessment is useful for better management of older patients with unsuspected problems, little is known about the reliability of the Comprehensive Geriatric Assessment to optimise the therapeutic approach in a specific patient with a malignant haemopathy. Particularly, the prognostic value of cognitive impairment in clinically fit older patients with haematological malignancies admitted to receive chemotherapy, are poorly investigated. This article investigated this question and tries to explain links between cognitive impairment and poor overall survival. Finally, this article tries to propose supportive interventions to reduce morbidity and mortality in older cancer patients with cognitive impairment.

(BELG J HEMATOL 2016;7(5):180–3)

Read more

P1.12 Identification of clinical and biological parameters predictive of chemotherapy completion and two-year overall survival in clinically fit older patients with haematological malignancies

BJH - volume 7, issue Abstract Book BHS, january 2016

S. Dubruille PhD, Y. Libert PhD, M. Roos , S. Vandenbossche , A. Collard , N. Meuleman MD, PhD, M. Maerevoet MD, A. Etienne , C. Reynaert , D. Razavi MD, PhD, D. Bron MD, PhD

Read more

P2.17 The respective value of the G8 screening and the Comprehensive Geriatric Assessment (CGA) for the identification of vulnerable older patients with hematological malignancies susceptible to benefit from chemotherapy

BJH - volume 5, issue Abstract Book BHS, january 2014

S. Dubruille PhD, Y. Libert PhD, M. Roos , S. Vandenbossche , N. Meuleman MD, PhD, M. Maerevoet MD, D. Razavi MD, PhD, D. Bron MD, PhD

Read more

P.13 G8 as a screening tool for older patients with malignant haemopathies: A surrogate for CGA?

BJH - 2013, issue BHS Abstractbook, january 2013

S. Dubruille PhD, M. Maerevoet MD, R. Roos , V. Vandenbossche , N. Meuleman MD, PhD, Y. Libert PhD, D. Bron MD, PhD

Read more